Should I buy or sell Ambrx Biopharma stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMAM shares. View AMAM analyst ratings or view top-rated stocks .

What is Ambrx Biopharma's stock price target for 2024?

8 brokerages have issued 12-month price targets for Ambrx Biopharma's shares. Their AMAM share price targets range from $9.00 to $32.00. On average, they anticipate the company's share price to reach $21.88 in the next twelve months. This suggests a possible upside of 80.8% from the stock's current price. View analysts price targets for AMAM or view top-rated stocks among Wall Street analysts .

How have AMAM shares performed in 2023?

Ambrx Biopharma's stock was trading at $2.27 at the start of the year. Since then, AMAM stock has increased by 433.0% and is now trading at $12.10. View the best growth stocks for 2023 here .

What ETFs hold Ambrx Biopharma's stock?

ETFs with the largest weight of Ambrx Biopharma (NYSE:AMAM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

When did Ambrx Biopharma IPO?

(AMAM) raised $126 million in an initial public offering on Friday, June 18th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen served as the underwriters for the IPO.

Who are Ambrx Biopharma's major shareholders?

Ambrx Biopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Federated Hermes Inc. (3.86%), FMR LLC (2.84%), NWI Management LP (0.26%), Simplex Trading LLC (0.00%), TD Asset Management Inc (0.18%) and Monashee Investment Management LLC (0.11%). Insiders that own company stock include Cormorant Asset Management, Lp, Daniel J O'connor and Sonja Nelson. View institutional ownership trends .

How do I buy shares of Ambrx Biopharma?

Shares of AMAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Ambrx Biopharma Stock Price, News & Analysis (NYSE:AMAM)

$12.10

+0.08 (+0.67%)

(As of 12/5/2023 ET)

Compare

Today's Range: $11.56
▼
$12.39
50-Day Range: $8.40
▼
$14.05
52-Week Range: $0.38
▼
$16.86

Volume: 980,405 shs
Average Volume: 1.70 million shs
Market Capitalization: $764.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.88

Ambrx Biopharma MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 80.8% Upside
$21.88 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.09
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$28.76 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.43) to ($1.29) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

239th out of 948 stocks

Biological Products, Except Diagnostic Industry

29th out of 147 stocks

4.4

Analyst's Opinion

Consensus Rating
Ambrx Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.88, Ambrx Biopharma has a forecasted upside of 80.8% from its current price of $12.10.
Amount of Analyst Coverage
Ambrx Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

N/A

Short Interest

Short Interest
There is no current short interest data available for AMAM.

0.0

Dividend Strength

Dividend Yield
Ambrx Biopharma does not currently pay a dividend.
Dividend Growth
Ambrx Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AMAM.

1.1

News and Social Media Coverage

News Sentiment
Ambrx Biopharma has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Ambrx Biopharma this week, compared to 2 articles on an average week.
Search Interest
Only 26 people have searched for AMAM on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Ambrx Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ambrx Biopharma insiders have bought 4,564.81% more of their company's stock than they have sold. Specifically, they have bought $28,763,117.00 in company stock and sold $616,598.00 in company stock.
Percentage Held by Insiders
Only 0.64% of the stock of Ambrx Biopharma is held by insiders.
Percentage Held by Institutions
77.28% of the stock of Ambrx Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ambrx Biopharma are expected to grow in the coming year, from ($1.43) to ($1.29) per share.
Price to Book Value per Share Ratio
Ambrx Biopharma has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ambrx Biopharma Stock (NYSE:AMAM)

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

AMAM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AMAM Stock News Headlines

December 3, 2023 | americanbankingnews.com

Ambrx Biopharma Inc. (NYSE:AMAM) Receives Average Recommendation of "Moderate Buy" from Brokerages

November 30, 2023 | americanbankingnews.com

Ambrx Biopharma (NYSE:AMAM) Given Market Outperform Rating at JMP Securities

December 6, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 29, 2023 | markets.businessinsider.com

Optimistic Outlook on Ambrx Biopharma’s Pipeline Justifies Buy Rating

November 28, 2023 | finance.yahoo.com

Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

November 18, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Twist Bioscience (TWST) and Ambrx Biopharma (AMAM)

November 14, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Ambrx Biopharma (AMAM) and Viridian Therapeutics (VRDN)

November 14, 2023 | markets.businessinsider.com

Goldman Sachs Keeps Their Hold Rating on Ambrx Biopharma (AMAM)

December 6, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

November 1, 2023 | msn.com

Ambrx Biopharma (AMAM) Price Target Increased by 8.17% to 25.79

October 26, 2023 | finance.yahoo.com

Cormorant Asset Management, LP Acquires New Stake in Ambrx Biopharma Inc

October 24, 2023 | msn.com

RBC Capital Maintains Ambrx Biopharma (AMAM) Outperform Recommendation

October 24, 2023 | seekingalpha.com

Ambrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO Data

October 23, 2023 | seekingalpha.com

Ambrx Biopharma: Potential With Recently Released Prostate Cancer Data

October 23, 2023 | markets.businessinsider.com

Analyst Ratings for Ambrx Biopharma

October 23, 2023 | finance.yahoo.com

Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments

October 16, 2023 | benzinga.com

Cancer Focused Ambrx Biopharma Stock Trading Lower Today - Here's Why

October 16, 2023 | finance.yahoo.com

Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress

October 13, 2023 | finance.yahoo.com

We're Hopeful That Ambrx Biopharma (NASDAQ:AMAM) Will Use Its Cash Wisely

September 26, 2023 | finance.yahoo.com

Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023

September 21, 2023 | msn.com

Why Shares of Ambrx Biopharma Soared This Week

September 21, 2023 | msn.com

Insider Trading: Ambrx Stock (NASDAQ:AMAM) Gains on Huge Insider Buy

September 18, 2023 | finance.yahoo.com

Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference

September 15, 2023 | nasdaq.com

Goldman Sachs Maintains Ambrx Biopharma Inc - ADR (AMAM) Neutral Recommendation

September 13, 2023 | markets.businessinsider.com

Where Ambrx Biopharma Stands With Analysts

September 5, 2023 | finance.yahoo.com

Ambrx to Present at the Baird and Morgan Stanley Global Healthcare Conferences

August 31, 2023 | msn.com

Ambrx Biopharma Has Surged 524% This Year. But It Could Just Be Getting Started.

See More Headlines

Receive AMAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/05/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:AMAM
CUSIP: N/A
CIK: 1836056
Web: ambrx.com
Phone: 858-875-2400
Fax: N/A
Employees: 87
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.88
High Stock Price Target: $32.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +80.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.28
Quick Ratio: 13.28

Sales & Book Value

Annual Sales: $4.09 million
Price / Sales: 186.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.05 per share
Price / Book: 3.97

Miscellaneous

Outstanding Shares: 63,150,000
Free Float: 62,746,000
Market Cap: $764.12 million
Optionable: Not Optionable
Beta: -2.07

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Daniel J. O'Connor J.D. (Age 58)
CEO, President & Director
Comp: $509.94k
Ms. Sonja Nelson CPA (Age 50)
Chief Financial Officer
Comp: $1.18M
Mr. Andrew P. Aromando (Age 54)
Chief Operating Officer
Dr. Ying J. Buechler Ph.D.
Chief Technology Officer
Dr. Shawn Shao-Hui Zhang Ph.D.
Chief Scientific Officer & GM of China
Mr. Jared Kelly
Senior VP, General Counsel & Corporate Secretary
Mr. Robert Azzara
Vice President of Human Capital
Dr. Sandra Aung Ph.D.
Chief Clinical Officer
Ms. Renu Vaish M.Sc. (Age 56)
Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMAM Stock Analysis - Frequently Asked Questions

Should I buy or sell Ambrx Biopharma stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMAM shares.
View AMAM analyst ratings or view top-rated stocks.
What is Ambrx Biopharma's stock price target for 2024?: 8 brokerages have issued 12-month price targets for Ambrx Biopharma's shares. Their AMAM share price targets range from $9.00 to $32.00. On average, they anticipate the company's share price to reach $21.88 in the next twelve months. This suggests a possible upside of 80.8% from the stock's current price.
View analysts price targets for AMAM or view top-rated stocks among Wall Street analysts.
How have AMAM shares performed in 2023?: Ambrx Biopharma's stock was trading at $2.27 at the start of the year. Since then, AMAM stock has increased by 433.0% and is now trading at $12.10.
View the best growth stocks for 2023 here.
What ETFs hold Ambrx Biopharma's stock?: ETFs with the largest weight of Ambrx Biopharma (NYSE:AMAM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

When did Ambrx Biopharma IPO?: (AMAM) raised $126 million in an initial public offering on Friday, June 18th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen served as the underwriters for the IPO.
Who are Ambrx Biopharma's major shareholders?: Ambrx Biopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Federated Hermes Inc. (3.86%), FMR LLC (2.84%), NWI Management LP (0.26%), Simplex Trading LLC (0.00%), TD Asset Management Inc (0.18%) and Monashee Investment Management LLC (0.11%). Insiders that own company stock include Cormorant Asset Management, Lp, Daniel J O'connor and Sonja Nelson.
View institutional ownership trends.
How do I buy shares of Ambrx Biopharma?: Shares of AMAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:AMAM) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ambrx Biopharma Stock Price, News & Analysis (NYSE:AMAM)

Ambrx Biopharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ambrx Biopharma Stock (NYSE:AMAM)

AMAM Stock Price History

AMAM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AMAM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™